Abstract
Under the supervision were 56 women of reproductive age with a diagnosis of bacterial vaginosis. Patients were
divided into 4 groups. The first group included 10 women who previously received antibiotic therapy on extragenital diseases.
Women are administered clindamycin vaginal cream of miconazole and followed by intravaginal drug use Revitaxa and probiotic
system Bififormula. The second group consisted of 10 women who have previously received antibiotic therapy on extragenital
diseases. Patients administered the drug Revitaxa and Bififormula without using antibiotics.The third group is formed of 23 women
who did not receive pre-antibiotic therapy. Prescribed combination therapy that, in addition to antibacterial cream included
intravaginal drug Revitaxa and probiotic system Bififormula. 23 women fourth group administered antibacterial cream and then
using the drug Revitaxa. Monitoring the effectiveness of the treatment was carried out by clinical and laboratory course of the
disease based on the dynamic changes of complaints of patients, assessment data pH measuring (7, 21 and 60 day observation
of treatment), assessment of the ecological community conducted a test system Femoflor 16 at 7 and 21 days of early treatment.
The results showed that the combined treatment of bacterial vaginosis with the use of antibacterial vaginal gel, Revitaxa and
probiotic Bififormula effectively and quickly restores the vaginal environment helps eliminate dysbiosis system and the rapid
return of the normal microflora vaginally, reduces the number of recurrences of bacterial vaginosis
References
Янковский ДС. Микробиом и здоровье женщины (обзор литературы) / ДС Янковский, ВП Широбоков, ЮГ Антипкин, ТФ Татарчук, ГС Дымент. Репродуктивная эндокринология. 2015;24:13-28.
Swidsinski A, Mendling W, Loening-Baucke V, Ladnoff A, et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol. 2005;106:1013-1023.
Patterson JL, Girerd PH, Karjane NW, Jefferson KK. Effect of biofilm phenotype on resistance of Gardnerella vaginalis to hydrogen peroxide and lactic acid. Am J Obstet Gynecol. 2007;197:170.
McMillan A, Dell M, Zellar MP, Cribby S, Martz S, Hong E, et al. Disruption of urogenital biofilms by lactobacilli. Colloids Surf B Biointerfaces. 2011;86:58-64.
Anukam K, Osazuwa E, Ahonkhai I, Ngwu M, Osemene G, Bruce AW. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microb Infect. 2006;8:1450-1454.
Cadieux P, Burton JC, Gardiner I. Lactobacillus strains and vaginal ecology. JAMA. 2002;287:1940-2041.
Bodean O, Munteanu O, Cirstoiu C, et al. Probiotics a helpful additional therapy for bacterial vaginosis. J Med Life. 2013;6(4):434-436.
Abad CL, Safdar N. The role of Lactobacillus probiotics in the treatment or prevention of urogenital infection – a systematic review. J Chemother. 2009;21(3):243-252.
Ehrström S, Daroczy K, Rylander E, Samuelsson C, et al. Lactic acid bacteria colonization and clinical outcome after probiotic supplementation in conventionally treated bacterial vaginosis and vulvovaginal candidiasis. Microbes Infect. 2010;12:691-699.